ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference

DENVER, CO / ACCESS Newswire / November 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that its management will participate at NobleCon21 - Noble Capital Markets' 21st Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.

Management will be presenting on Wednesday, December 3rd at 10:30 a.m. Eastern time. A high-definition video webcast of the presentation will be available the following day on the Company's website (www.aytubio.com), and as part of a complete catalog of presentations available at Noble Capital Markets' Conference website (www.nobleconference.com) and on Channelchek (www.channelchek.com), the investor portal created by Noble. The webcast will be archived on the Company's website, the NobleCon website and on Channelchek for 90 days following the event.

Management will also be conducting one-on-one meetings at the conference. Investors should contact their Noble representatives, or Robert Blum of Lytham Partners at aytu@lythampartners.com, to schedule one-on-one meetings.

About Aytu BioPharma

Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUAâ„¢ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD) and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.

Contacts for Investors

Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com

Robert Blum
Lytham Partners
aytu@lythampartners.com

SOURCE: Aytu BioPharma, Inc.



View the original press release on ACCESS Newswire

Recent Quotes

View More
Symbol Price Change (%)
AMZN  234.42
+0.54 (0.23%)
AAPL  286.19
+3.09 (1.09%)
AMD  215.24
-4.52 (-2.06%)
BAC  53.19
-0.05 (-0.09%)
GOOG  316.02
+0.90 (0.29%)
META  647.10
+6.23 (0.97%)
MSFT  490.00
+3.26 (0.67%)
NVDA  181.46
+1.54 (0.86%)
ORCL  201.10
+0.16 (0.08%)
TSLA  429.24
-0.90 (-0.21%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.